Preoperative cholangitis is an independent risk factor for mortality in patients after pancreatoduodenectomy for pancreatic cancer - 08/12/20
Abstract |
Objectives |
Preoperative biliary stenting is required for patients with obstructive jaundice from pancreatic adenocarcinoma who are receiving neoadjuvant chemotherapy. While in most patients this approach results in durable biliary drainage, some patients develop cholangitis during neoadjuvant treatment. Further, several studies have shown that preoperative cholangitis in patients with hepatobiliary malignancies can result in substantially unfavorable outcomes. The aim of this study was to evaluate the impact of preoperative cholangitis in patients who underwent pancreaticoduodenectomy after completing neoadjuvant chemotherapy.
Methods |
Participants: all adult patients (n = 449) diagnosed with pancreatic adenocarcinoma from January 1st, 2013 to March 31st, 2018 who pursued treatment at the Massachusetts General Hospital were screened. Of these 449 patients, 97 met final inclusion criteria of receiving neoadjuvant chemotherapy with intent to pursue curative surgery. Data were collected via retrospective chart review including baseline characteristics, survival, episodes of preoperative cholangitis, and surgical complications.
Results |
In patients completing successful pancreaticoduodenectomy surgery, preoperative cholangitis is associated with increased mortality (HR 2.67, 95% CI:1.16–6.13). This finding is independent of postoperative outcomes or tumor recurrence rate. The presence of cholangitis did not impact completion of neoadjuvant chemotherapy (92% vs 85%, p = 0.5) or ability to proceed to surgery (76% vs 75%, p = 1.0). Preoperative cholangitis was not associated with postoperative morbidity (42.1% vs 45.1%, p = 1.0).
Conclusions |
One episode of cholangitis during neoadjuvant chemotherapy is associated with increased mortality following successful pancreaticoduodenectomy, independent of immediate postoperative outcomes or tumor recurrence. Preoperative cholangitis does not affect ability to pursue neoadjuvant chemotherapy or complete successful surgery. Patients who develop cholangitis during the neoadjuvant chemotherapy treatment phase may reflect a distinct phenotype of patients with PDAC with a complex and more challenging clinical course.
Le texte complet de cet article est disponible en PDF.Highlights |
• | Biliary stenting is often required in patients with pancreatic carcinoma who undergo neoadjuvant chemotherapy. |
• | Despite stenting, some patients develop cholangitis. The impact of which is unclear. |
• | Preoperative cholangitis is associated with increased mortality. Preoperative cholangitis does not affect ability to complete neoadjuvant chemotherapy or successful surgery. |
• | Clinicians should be aware of the detrimental impact of preoperative cholangitis on patients undergoing neoadjuvant chemotherapy. |
Keywords : Whipple, Cholangitis, Biliary, Stenting, ERCP
Plan
Vol 221 - N° 1
P. 134-140 - janvier 2021 Retour au numéro
Article précédent
- Cryoablation: A promising non-operative therapy for low-risk breast cancer
- Zaina Habrawi, Michael W. Melkus, Sonia Khan, James Henderson, Luis Brandi, Victoria Chu, Rakhshanda Layeequr Rahman
- Is the placement of jejunostomy tubes in patients with esophageal cancer undergoing esophagectomy associated with increased inpatient healthcare utilization? An analysis of the National Readmissions Database
- Richard Zheng, Arturo J. Rios-Diaz, Spencer Liem, Courtney L. Devin, Nathaniel R. Evans, Ernest L. Rosato, Francesco Palazzo, Adam C. Berger
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?